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Abstract 
Background: Both in endemic countries and in imported malaria, changes in total and differential leukocyte count 
during Plasmodium falciparum infection have been described. To study the exact dynamics of differential leukocyte 
counts and their ratios, they were monitored in a group of healthy non-immune volunteers in two separate Con-
trolled Human Malaria Infection (CHMI) studies.
Methods: In two CHMI trials, CHMI-a and CHMI-b, 15 and 24 healthy malaria-naïve volunteers, respectively, were 
exposed to bites of infected mosquitoes, using the P. falciparum research strain NF54 and the novel clones NF135.C10 
and NF166.C8. After mosquito bite exposure, twice-daily blood draws were taken to detect parasitaemia and to moni-
tor the total and differential leukocyte counts. All subjects received a course of atovaquone–proguanil when meeting 
the treatment criteria.
Results: A total of 39 volunteers participated in the two trials. Thirty-five participants, all 15 participants in CHMI-a 
and 20 of the 24 volunteers in CHMI-b, developed parasitaemia. During liver stage development of the parasite, the 
median total leukocyte count increased from 5.5 to 6.1 × 109 leukocytes/L (p = 0.005), the median lymphocyte count 
from 1.9 to 2.2 (p = 0.001) and the monocyte count from 0.50 to 0.54 (p = 0.038). During the subsequent blood 
stage infection, significant changes in total and differential leukocyte counts lead to a leukocytopenia (nadir median 
3.3 × 109 leukocytes/L, p = 0.0001), lymphocytopenia (nadir median 0.7 × 109 lymphocytes/L, p = 0.0001) and a 
borderline neutropenia (nadir median 1.5 × 109 neutrophils/L, p = 0.0001). The neutrophil to lymphocyte count ratio 
(NLCR) reached a maximum of 4.0. Significant correlations were found between parasite load and absolute lympho-
cyte count (p < 0.001, correlation coefficient − 0.46) and between parasite load and NLCR (p < 0.001, correlation 
coefficient 0.50). All parameters normalized after parasite clearance.
Conclusions: During the clinically silent liver phase of malaria, an increase of peripheral total leukocyte count and 
differential lymphocytes and monocytes occurs. This finding has not been described previously. This increase is fol-
lowed by the appearance of parasites in the peripheral blood after 2–3 days, accompanied by a marked decrease in 
total leukocyte count, lymphocyte count and the neutrophil count and a rise of the NLCR.
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Background
Controlled Human Malaria Infection (CHMI) is a well-
established clinical model that was developed for the 
evaluation of candidate malaria vaccines and drugs [1]. 
In this model, healthy volunteers are infected by malaria 
sporozoites via exposure to the bites of infected mosqui-
toes or via inoculation by needle and syringe [2]. CMHI 
studies have traditionally been performed using the 
Plasmodium falciparum strain NF54, which is thought 
to originate from Africa [3]. More recently, the clones 
NF135.C10, and NF166.C8, originating from P. falcipa-
rum strains from Cambodia and Guinea, respectively, 
have been added to the CHMI portfolio [4–6]. In the 
present study, the CHMI model is used to study total and 
differential leukocyte count changes and their ratios dur-
ing the liver phase and blood phase of malaria.
Changes in total and differential leukocyte count during 
P. falciparum infection have been described in both clini-
cal studies and CHMI studies previously. In clinical studies, 
both in endemic countries and in patients with imported 
malaria [7–10], the most pronounced change is the decrease 
of peripheral lymphocytes. Lymphocytopenia has been 
observed in 45 to 63% of patients with an imported P. falcipa-
rum infection, but was less prominent in patients with some 
degree of anti-malarial immunity [11, 12]. In a recent large 
cross-sectional study on leukocyte count changes in return-
ing travellers, malaria was the second most common cause of 
absolute lymphocytopenia [13]. Differential leukocyte count 
changes have also been studied in patients with imported 
malaria. The neutrophil-to-lymphocyte count ratio (NLCR), 
which was introduced by Zahorec et  al. as a parameter of 
systemic inflammation in critically ill surgical and medical 
patients [14], correlated with parasitaemia and normalized 
after parasite clearance in patients with imported malaria [11, 
12]. One study showed correlations between parasitaemia 
and both the monocyte to lymphocyte count ratio (MLCR) 
and neutrophil to monocyte count ratio (NMCR) [11].
In CHMI studies, decreases in total leukocyte count, neu-
trophil count and lymphocyte count have been described 
during the blood phase [15–20], but could not evaluate leu-
kocyte changes during liver stages of the parasite life cycle.
In the present study, the changes of differential leuko-
cyte counts and their ratios were monitored during the 
liver phase and the development of detectable blood 
parasitaemia in a group of healthy non-immune volun-
teers in the CHMI model using the NF54, NF166.C8 and 
NF135.C10 P. falciparum clones.
Methods
Study design
The present study was performed using two Controlled 
Human Malaria Infection studies, CHMI-a and CHMI-b [4]. 
Healthy malaria-naïve adult Dutch volunteers were recruited 
at the Harbour Hospital, Rotterdam, after signing informed 
consent. In CHMI-a, fifteen subjects were randomly allo-
cated to three groups of n = 5, to be infected by bites of five 
mosquitoes per subject carrying either the NF54 strain of 
P. falciparum, the NF135.C10 clone or the novel NF166.C8 
clone. In CHMI-b, 24 subjects were randomly allocated to 
six groups of n = 4, to bites by one, two or five mosquitoes 
carrying either NF135.C10 or NF166.C8. From day 5 after 
exposure, subjects were seen in clinic twice daily for registra-
tion of vital parameters and adverse events and for venous 
blood draws for thick blood smear, qPCR, and a wide range 
of laboratory parameters including differential leukocyte 
counts. Plasmodium falciparum parasitaemia was quanti-
fied by qPCR as described before [21]. In CHMI-a, subjects 
were treated with atovaquone–proguanil 1000/400  mg 
daily for 3 days upon their first positive thick blood smear, 
defined as ≥ 2 parasites per 225 high-powered fields (equiva-
lent to 0.5 µL blood). In CHMI-b, subjects were treated with 
the same regimen as soon as 2 consecutive blood samples 
were positive by qPCR, defined as > 500 parasites/mL. This 
change in treatment initiation between the two studies was 
implemented to minimize safety risks following a cardiac 
serious adverse event in a previous study [15, 22]. Daily thick 
blood smears and qPCR were continued after treatment 
until complete clearance of asexual parasites.
Data selection
This study focused on leukocyte count changes during 
the liver stage and blood stage of the malaria infection 
in the participants of CHMI-a and CHMI-b. Data from 
the measurements taken during the liver phase in both 
studies were combined. However, the described differ-
ences in methodology regarding the initiation of treat-
ment in both studies did not permit combination of 
blood phase CHMI-a and CHMI-b data. For this phase, 
the data of only CHMI-b were used, as in this study the 
subjects who remained qPCR negative, but received the 
same treatment as the parasitaemic subjects, could be 
used as a negative control group to exclude an effect of 
the atovaquone–proguanil on the evaluated parameters.
Statistical analysis
To determine whether the parameters of interest changed 
over time a Friedman test was performed. Next, a more 
detailed analysis of the timing of these changes was done 
using a linear model. Correlations were tested with the 
Spearman’s rank-order correlation. Data were not nor-
mally distributed and given as median (interquartile 
range) unless stated otherwise.
Definitions
Leukocytopenia  Leukocyte count < 4.0 × 109/L;
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Lymphocytopenia  L y m p h o c y t e 
count < 1.0 × 109/L;
Neutropenia  Neutrophil count < 1.5 × 109/L.
Day of treatment (DT)  The day the subject started a 
3-day course of atovaquone–
proguanil, directly upon 
meeting the treatment cri-
teria. The days from 2  days 
before until 3  days after this 
day are named DT  −  2 to 
DT + 3.
Liver phase  The subjects who eventually developed 
parasitaemia were regarded as being in 
the liver phase on day 5 and 6 of the 
study protocol, when the peripheral 
blood samples of all subjects were still 
qPCR negative.
Detectable blood parasitaemia  Detectable blood 
parasitaemia is 
defined as qPCR pos-
itive, a method with a 
detection limit of 50 
parasites per mL.
Results
Development of parasitaemia and phases of the infection
In CHMI-a, all participants developed parasitaemia, 
with a median prepatent period of 8  days (range 6.5–
10.5 days), determined by thick blood smear, upon which 
curative treatment was initiated. As determined retro-
spectively, all subjects were still qPCR negative on day 
5 and 6 of the study protocol. Of the 24 participants in 
CHMI-b, twenty (83%) developed parasitaemia. The 
median prepatent period as determined by qPCR was 
7  days (range 7–9  days) and the median time between 
exposure and the day the treatment criteria were met 
(hereafter called day of treatment [DT]) was 8  days 
(range 7–11 days).
For CHMI-b, the data from 2 days before DT (DT − 2) 
until 3 days after DT (DT + 3) were synchronized on DT 
(Fig. 1). On DT − 2, four subjects had a positive qPCR, 
all with a low parasitaemia (385–713 parasites/mL) and 
did not meet the treatment criteria at that moment. The 
number of parasitaemic subjects increased to nine sub-
jects on DT − 1. The median parasite load on DT, when 
all patients met the treatment criteria, was 6265 parasites 
per mL. Hereafter the parasite load declined to 1099 on 
DT + 1 and 100 parasites per ml on DT + 2.
Baseline day 5 day 6 DT-2 DT-1 DT DT+1 DT+2 DT+3 day 35
0.0
2.0
4.0
6.0
8.0
Liver phase
Leukocytes x10 9 / L
Neutrophils x109 / L
Log parasitemia
Lymphoctes x109 / L
Monocytes x109 / L
Fig. 1 Changes in total and differential leukocyte counts in the 20 subjects who developed malaria in CHMI-b. The data are shown as medians 
(dots) and interquartile ranges (whiskers). The data from DT − 2 until DT + 3 were synchronized on DT
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Changes in differential leukocyte counts and count ratios 
during the liver phase
All 35 subjects who developed detectable parasitaemia in 
CHMI-a and CHMI-b were still qPCR negative at day 5 
and 6 of the study protocol, and the infection was there-
fore regarded as being in the liver phase [23]. During 
this phase an increase of the total leukocyte count, lym-
phocyte count and the monocyte count was observed in 
the 35 subjects who developed parasitaemia later on in 
CHMI-a and CHMI-b. Changes in neutrophil count and 
the differential cell count ratios were not significant. No 
significant changes were observed in the four subjects 
who remained qPCR negative in CHMI-b. No differences 
between the total or differential leukocyte counts were 
found between subjects infected with NF54 strain, the 
NF135.C10 clone or the NF166.C8 clone (Table 1).
Changes in differential leukocyte counts and count ratios 
after the liver phase
In the group of twenty parasitaemic subjects in CHMI-
b, highly significant changes in the total leukocyte count 
and differential cell counts of neutrophils, lymphocytes 
and monocytes were observed in the days before DT 
and during treatment (Table 2 and Fig. 1). These changes 
were not seen in non-parasitaemic individuals (Addi-
tional file 1: Table S1 and Additional file 2: Figure S1). Of 
interest, both parasitaemic and non-parasitaemic indi-
viduals received anti-malarial treatment, thus excluding 
Table 1 The course of differential leukocyte counts and their ratios during the liver phase in the subjects who develop 
malaria
The data of CHMI-a and CHMI-b are shown separately and combined
Data in this table are not normally distributed and shown as median (interquartile range). p values in this table were derived from Friedman tests
Leukocytes × 109/L Neutrophils × 109/L Lymphocytes × 109/L Monocytes × 109/L NLCR MLCR NMCR
CHMI-a (n = 15)
 Baseline 5.8 (5.3–6.5) 3.1 (2.9–3.3) 1.9 (1.9–2.3) 0.51 (0.48–0.58) 1.6 (1.4–1.7) Baseline 5.8 (5.3–6.5)
 Day 5 6.8 (6.1–7.3) 3.6 (2.9–4.0) 2.3 (2.0–2.5) 0.55 (0.46–0.63) 1.6 (1.4–1.8) Day 5 6.8 (6.1–7.3)
 Day 6 6.9 (5.8–7.6) 3.2 (2.7–4.1) 2.4 (1.9–2.7) 0.55 (0.49–0.58) 1.3 (1.1–1.9) Day 6 6.9 (5.8–7.6)
 p value 0.105 0.721 0.140 0.208 0.623 p value 0.105
CHMI-b (n = 20)
 Baseline 5.1 (4.9–6.1) 2.8 (2.5–3.1) 1.6 (1.5–2.0) 0.48 (0.35–0.60) 1.8 (1.1–2.0) 0.3 (0.2–0.3) 5.8 (4.7–8.3)
 Day 5 5.7 (5.4–7.2) 3.1 (2.2–3.6) 2.0 (1.7–2.5) 0.49 (0.43–0.60) 1.3 (1.0–2.1) 0.2 (0.2–0.3) 5.9 (4.8–7.2)
 Day 6 6.0 (5.3–6.9) 3.0 (2.4–3.8) 2.2 (1.9–2.4) 0.53 (0.46–0.65) 1.4 (1.1–1.8) 0.2 (0.2–0.3) 5.3 (4.6–7.1)
 p value 0.051 0.195 0.004 0.012 0.165 0.196 0.848
Combined (n = 35)
 Baseline 5.5 (5.0–6.2) 2.9 (2.6–3.2) 1.9 (1.6–2.2) 0.50 (0.38–0.60) 1.7 (1.3–2.0) 0.3 (0.2–0.3) 6.1 (4.8–8.4)
 Day 5 6.1 (5.5–7.2) 3.3 (2.5–3.7) 2.2 (1.8–2.5) 0.50 (0.43–0.54) 1.5 (1.1–1.9) 0.2 (0.2–0.3) 6.1 (4.9–8.1)
 Day 6 6.1 (5.5–7.0) 3.0 (2.6–3.9) 2.2 (1.9–2.6) 0.54 (0.47–0.62) 1.4 (1.1–1.8) 0.2 (0.2–0.3) 5.7 (4.8–7.2)
 p value 0.005 0.413 0.001 0.038 0.121 0.368 0.971
Table 2 The course of differential leukocyte counts and their ratios in the 20 subjects who develop malaria in CHMI-b
Data in this table are not normally distributed and shown as median (interquartile range). p values in this table were derived from Friedman tests
Leuko-
cytes × 109/L
Neutro-
phils × 109/L
Lympho-
cytes × 109/L
Mono-
cytes × 109/L
NLCR MLCR NMCR Parasite load 
parasites/mL
Baseline 5.1 (4.9–6.1) 2.8 (2.5–3.1) 1.6 (1.5–2.0) 0.48 (0.35–0.60) 1.8 (1.1–2.0) 0.3 (0.2–0.3) 5.8 (4.7–8.3) N/A
DT − 2 5.8 (5.4–6.8) 3.0 (2.3–3.7) 2.1 (1.9–2.4) 0.49 (0.43–0.61) 1.4 (1.0–1.7) 0.2 (0.2–0.3) 5.6 (4.3–6.8) 0 (0–0)
DT − 1 5.8 (5.3–6.6) 2.9 (2.6–3.5) 2.0 (1.5–2.3) 0.55 (0.46–0.65) 1.4 (1.1–2.1) 0.3 (0.2–0.3) 5.2 (4.5–6.7) 0 (0–374)
DT 5.6 (4.8–6.1) 3.1 (2.8–3.6) 1.6 (0.9–2.0) 0.53 (0.40–0.58) 2.2 (1.4–3.8) 0.4 (0.4–0.5) 6.4 (5.0–8.0) 6265 (1306–12,152)
DT + 1 4.4 (3.9–4.7) 3.0 (2.5–3.2) 0.8 (0.6–1.1) 0.44 (0.30–0.60) 4.0 (2.2–5.3) 0.5 (0.5–0.6) 6.9 (5.4–9.5) 1099 (159–19,494)
DT + 2 3.3 (2.9–4.0) 1.9 (1.7–2.5) 0.7 (0.6–1.2) 0.32 (0.24–0.49) 2.6 (1.7–3.7) 0.5 (0.3–0.6) 6.2 (4.1–8.0) 100 (1–20,337)
DT + 3 3.4 (2.7–3.7) 1.5 (1.3–1.9) 1.0 (0.8–1.3) 0.36 (0.28–0.60) 1.6 (1.1–2.2) 0.5 (0.3–0.6) 3.6 (2.8–5.4) 1 (0–305)
Day 35 6.2 (5.2–7.2) 2.8 (2.3–3.3) 2.2 (1.9–3.0) 0.53 (0.44–0.71) 1.2 (0.9–1.3) 0.2 (0.2–0.2) 5.6 (4.1–6.4) 0 (0–0)
p value < 0.0001 < 0.0001 < 0.0001 0.002 < 0.0001 < 0.0001 < 0.0001 < 0.0001
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an effect of atovaquone–proguanil treatment on the 
observed changes.
Linear model analysis showed that in the individu-
als who develop parasitaemia, the leukocyte count 
remained stable until DT  −  1 and then showed a fall, 
which continued until it reached its nadir on DT +  2, 
with a median of 3.3  ×  105 leukocytes/L. On day 
DT + 2, a leukocytopenia was observed in 70% (14/20) 
of the subjects. The absolute neutrophil count started 
to decrease on DT − 1 to a median value of 1.5 × 105 
neutrophils/L on DT  +  3. Neutropenia was found in 
40% (8/20) of the subjects on this day. A steady fall in 
absolute lymphocyte count was observed from DT − 2 
until DT + 2, when the median lymphocyte count was 
0.7  ×  105 lymphocytes/L. The percentage of subjects 
with an absolute lymphocytopenia increased from 30% 
(6/20) on DT to 70% (14/20) 2  days later. The median 
absolute monocyte counts remained within the normal 
range, but showed a mild drop on DT + 2. On day 35 of 
the study protocol, all parameters had returned to base-
line values. The evaluated parameters did not differ sig-
nificantly between subgroups of subjects infected with 
NF166.C8 and NF135.C10.
The differential cell count ratios were also found to 
change significantly over time using the Friedman test 
(Table  1, Fig.  2). The linear model analysis showed a 
gradual rise of the NLCR, reaching a maximum of 4.0 on 
DT + 1. After DT + 1 a rapid decrease was observed. The 
MLCR showed a rise from DT − 2 to DT + 1 after which 
it decreased. The NMCR seemed to show a rise followed 
by a fall but these changes were not significant in the lin-
ear model analysis.
In the four subjects that remained qPCR negative 
throughout the study period, the differential leukocyte 
counts remained within normal values and no significant 
changes in cell counts or cell count ratios were observed. 
All four received a full course of atovaquone–proguanil 
at day 13 of the study protocol (Additional file 1: Table S1 
and Additional file 3: Figure S2).
Correlations
Significant correlations were found between parasite 
load and absolute lymphocyte count (p  <  0.001, cor-
relation coefficient − 0.46) and between parasite load 
and NLCR (p  <  0.001, correlation coefficient 0.50) 
in CHMI-b. Correlations between parasite load and 
total leukocyte count, MLCR and NMCR were signifi-
cant, but weak (p = 0.004, Spearman’s rho  (rs) − 0.23, 
p < 0.001,  rs 0.36 and p = 0.003,  rs 0.23, respectively). 
There was no significant correlation between parasite 
load and absolute neutrophil count or absolute mono-
cyte count.
Baseline day 5 day 6 DT-2 DT-1 DT DT+1 DT+2 DT+3 day 35
0.0
4.0
8.0
12.0
NLCR
MLCR
NMCR
Log parasitemia
Liver phase
Fig. 2 Changes in differential cell count ratios in the 20 subjects who developed malaria in CHMI-b. The data are shown as medians (dots) and 
interquartile ranges (whiskers). The data from DT − 2 until DT + 3 were synchronized on DT
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Discussion
The present CHMI study shows an increase in total leu-
kocyte, lymphocyte and monocyte count during para-
site liver stages of infected subjects. Upon blood stage 
infection, a decrease is observed in total leukocyte, neu-
trophil, lymphocyte and monocyte count; these changes 
clearly relate to the occurrence of blood parasitaemia 
and are not caused by treatment with atovaquone–pro-
guanil, as shown by the control group of four subjects, 
who remained non-parasitaemic until day 13 after 
mosquito exposure and were then treated with a full 
course of atovaquone–proguanil. Although it cannot be 
excluded that one or more of these four non-parasitae-
mic subjects had a liver stage infection when treatment 
was initiated, we regard it more likely that no sporo-
zoite transmission occurred. In this group, no changes 
in total or differential leukocyte counts were observed 
during the study period.
The increase of the total leukocyte count, lymphocytes 
and monocytes during liver stage development has not 
been previously reported. During the clinically silent liver 
phase of malaria, only a relatively low number of hepato-
cytes become infected and the host immune responses 
to this stage of the parasite are poorly understood [24]. 
Previous CHMI studies have studied inflammatory 
parameters and cellular and humoral immune responses, 
but only demonstrated changes in these markers during 
the blood phase of the infection [15–20, 25]. The find-
ing that the total leukocyte count, lymphocyte count and 
monocyte count show an increase during the liver phase 
is remarkable and further studies are needed to confirm 
this finding and to elucidate its underlying pathophysi-
ological mechanism.
The most pronounced change after the liver phase 
is a fall in lymphocyte count that starts on DT  −  1 
and reaches its nadir at 0.7  ×  105 lymphocytes/L on 
DT  +  2, when 65% of subjects are lymphocytopenic. 
The neutrophil count only starts to show a significant 
fall after DT. These changes are reflected in the NLCR, 
which shows a steep rise to 4.0 on DT  +  2. In com-
parison, in a previous study on patients with imported 
malaria the median NLCR on admission of all patients 
was 3.2, and 3.5 in patients with a severe P. falciparum 
infection [12].
Lymphocytopenia has been described in several 
large cohorts of patients with malaria [9, 26–28] and 
is highly prevalent in symptomatic travelers with 
imported malaria [12]. The correlations between para-
site and lymphocyte count and between parasite load 
and NLCR were also demonstrated in a study by Ber-
ens-Riha et  al. [11], in which patients were stratified 
according to their immune status. Both the MLCR and 
the NLCR were found to be lower in semi-immune 
patients as compared to non-immune patients. In the 
present study, all subjects were non-immune. White 
blood cell count changes have also been described in 
previous CHMI studies. In a study on clinical mani-
festations in CHMI with P. falciparum, Church et  al. 
described a decrease in total white blood cell count 
and in neutrophil count, but not in lymphocyte count, 
with the nadir occurring 2 days after therapy initiation 
[15]. A decrease in lymphocyte count was observed 
in several studies involving sporozoite infection after 
mosquito bite exposure [16–19] and in a study using 
experimental inoculation with a low number of para-
sitized erythrocytes [20]. These observations are in line 
with the findings described here. As no measurements 
are available between DT + 3 and the end of the study 
protocol at day 35, we are not able to monitor when the 
changes observed, started to normalize after treatment. 
This is an important limitation of the study.
Several mechanisms have been proposed as an expla-
nation for malaria induced lymphocytopenia. A tempo-
rary reallocation of lymphocytes has been suggested, 
which is supported by the observation that lymphocytes 
rapidly re-emerge in the peripheral circulation after 
treatment is initiated [29]. Others suggest that the solu-
ble Fas ligand induces apoptosis of lymphocytes, which 
has been observed both in vitro and in healthy donors 
from endemic areas [30–34], and a previous CHMI 
study found an increased production of Granzyme B, 
which is also know to induce apoptosis, in exposed indi-
viduals, [35]. Both mechanisms though might be partly 
responsible for the observed fall in lymphocyte cell 
count.
Conclusions
In a setting of controlled human malaria infection in 
healthy non-immune volunteers, an initial increase of 
peripheral total leukocyte count and differential lym-
phocytes and monocytes was observed during liver stage 
infection of 35 infected volunteers. This rise seems to 
indicate the presence of a malaria infection and is fol-
lowed 2–3  days later by the appearance of parasites in 
the peripheral blood, which is accompanied by a marked 
decrease in total leukocyte count, lymphocyte count 
and the neutrophil count and a rise of the NLCR. Both 
the lymphocyte count and the NLCR correlated with 
blood parasitaemia, and all parameters had normalized 
3–4 weeks after parasite clearance. The non-parasitaemic 
control group in this study excludes a treatment-related 
effect.
Page 7 of 8van Wolfswinkel et al. Malar J  (2017) 16:457 
Abbreviations
CHMI: controlled human malaria infection; NLCR: neutrophil to lymphocyte 
count ratio; MLCR: monocyte to lymphocyte count ratio; NMCR: neutrophil to 
monocyte count ratio; qPCR: quantitative polymerase chain reaction.
Authors’ contributions
MEvW was responsible for the data analysis and writing of the manuscript. 
MCCL, CCH, RWS, JJVH and PJVG contributed to the writing and revising of 
the manuscript. MCCL, LJW, CCH, RWS, JJVH and PJVG were involved in the 
collection of clinical data. RK was responsible for collection of patient data and 
database management. All authors read and approved the final manuscript.
Author details
1 Institute for Tropical Diseases, Harbour Hospital, Rotterdam, The Netherlands. 
2 Department of Medical Microbiology and Infectious Diseases, Erasmus MC 
and Harbour Hospital, Rotterdam, The Netherlands. 3 Department of Parasitology, 
Leiden University Medical Center, Leiden, The Netherlands. 4 Department of Medi-
cal Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets analysed during the current study are available from the cor-
responding author on reasonable request.
Consent for publication
Is regulated within informed consent procedure of participating volunteers.
Ethics approval and consent to participate
These studies were approved by the Netherlands’ Central Committee on 
Human Research (CCMO NL41004.078.12 and NL48704.000.14, respectively) 
and are registered with ClinicalTrials.gov (Registration Numbers NCT01627951 
and NCT02149550, respectively) [4].
Funding
The CHMI studies described here were supported by Top Institute Pharma 
[Grant T4-102] and the Bill and Melinda Gates Foundation [Grant opp1080385], 
respectively. The Port of Rotterdam supported the Harbour Hospital with a 
grant to study infectious diseases in the region of Rotterdam, the Netherlands. 
Neither financial sponsor was involved in the respective study design, in the 
collection, analysis or interpretation of data, or in the writing of the report or 
in the decision to submit for publication.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 6 July 2017   Accepted: 4 November 2017
Additional files
Additional file 1: Table S1. Differential leukocyte counts and their ratios 
in the 4 non-parasitemic subjects in CHMI-b.
Additional file 2: Figure S1. Changes in total and differential leukocyte 
counts in the 4 subjects who did not develop malaria in CHMI-b. The data 
are shown as medians (dots) and interquartile ranges (whiskers). None of 
the changes in this group were statistically significant.
Additional file 3: Figure S2. Changes in differential cell count ratios 
in the 4 subjects who did not develop malaria in CHMI-b. The data are 
shown as medians (dots) and interquartile ranges (whiskers). None of the 
changes in this group were statistically significant.
References
 1. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human chal-
lenge infections can accelerate clinical malaria vaccine development. Nat 
Rev Immunol. 2011;11:57–64.
 2. Sulyok M, Ruckle T, Roth A, Murbeth RE, Chalon S, Kerr N, et al. DSM265 
for Plasmodium falciparum chemoprophylaxis: a randomised, double 
blinded, phase 1 trial with controlled human malaria infection. Lancet 
Infect Dis. 2017;17:636–44.
 3. Su XZ. Tracing the geographic origins of Plasmodium falciparum malaria 
parasites. Pathog Glob Health. 2014;108:261–2.
 4. McCall MMB, Wammes LJ, Langenberg MCC, van Gemert GJ, Walk J, 
Hermsen CC, et al. Infectivity of Plasmodium falciparum sporozoites 
determines emerging in a primary malaria infection. Sci Transl Med. 
2017;9:eaag2490.
 5. Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, 
Heinrichs MJ, Siebelink-Stoter R, et al. NF135.C10: a new Plasmodium 
falciparum clone for controlled human malaria infections. J Infect Dis. 
2013;207:656–60.
 6. Eldering M, Morlais I, van Gemert GJ, van de Vegte-Bolmer M, Graumans 
W, Siebelink-Stoter R, et al. Variation in susceptibility of African Plasmo-
dium falciparum malaria parasites to TEP1 mediated killing in Anopheles 
gambiae mosquitoes. Sci Rep. 2016;6:20440.
 7. Lisse IM, Aaby P, Whittle H, Knudsen K. A community study of T lym-
phocyte subsets and malaria parasitaemia. Trans R Soc Trop Med Hyg. 
1994;88:709–10.
 8. Kassa D, Petros B, Mesele T, Hailu E, Wolday D. Characterization of 
peripheral blood lymphocyte subsets in patients with acute Plasmodium 
falciparum and P. vivax malaria infections at Wonji Sugar Estate, Ethiopia. 
Clin Vaccine Immunol. 2006;13:376–9.
 9. Richards MW, Behrens RH, Doherty JF. Hematologic changes in 
acute, imported Plasmodium falciparum malaria. Am J Trop Med Hyg. 
1998;59:859.
 10. Ladhani S, Lowe B, Cole AO, Kowuondo K, Newton CR. Changes in white 
blood cells and platelets in children with falciparum malaria: relationship 
to disease outcome. Br J Haematol. 2002;119:839–47.
 11. Berens-Riha N, Kroidl I, Schunk M, Alberer M, Beissner M, Pritsch M, et al. 
Evidence for significant influence of host immunity on changes in dif-
ferential blood count during malaria. Malar J. 2014;13:155.
 12. van Wolfswinkel ME, Vliegenthart-Jongbloed K, Melo MD, Wever PC, 
McCall MB, Koelewijn R, et al. Predictive value of lymphocytopenia and 
the neutrophil-lymphocyte count ratio for severe imported malaria. Malar 
J. 2013;12:101.
 13. Herbinger KH, Hanus I, Beissner M, Berens-Riha N, Kroidl I, von Sonnen-
burg F, et al. Lymphocytosis and lymphopenia induced by imported 
infectious diseases: a controlled cross-sectional study of 17,229 diseased 
German travelers returning from the tropics and subtropics. Am J Trop 
Med Hyg. 2016;94:1385–91.
 14. Zahorec R. Ratio of neutrophil to lymphocyte counts–rapid and simple 
parameter of systemic inflammation and stress in critically ill. Bratisl Lek 
Listy. 2001;102:5–14.
 15. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical 
manifestations of Plasmodium falciparum malaria experimentally induced 
by mosquito challenge. J Infect Dis. 1997;175:915–20.
 16. Rzepczyk CM, Stamatiou S, Anderson K, Stowers A, Cheng Q, Saul A, et al. 
Experimental human Plasmodium falciparum infections: longitudinal 
analysis of lymphocyte responses with particular reference to gamma 
delta T cells. Scand J Immunol. 1996;43:219–27.
 17. De Mast Q, Sweep FC, McCall M, Geurts-Moespot A, Hermsen C, Calandra 
T, et al. A decrease of plasma macrophage migration inhibitory factor 
concentration is associated with lower numbers of circulating lympho-
cytes in experimental Plasmodium falciparum malaria. Parasite Immunol. 
2008;30:133–8.
 18. Scholzen A, Teirlinck AC, Bijker EM, Roestenberg M, Hermsen CC, Hoffman 
SL, et al. BAFF and BAFF receptor levels correlate with B cell subset activa-
tion and redistribution in controlled human malaria infection. J Immunol. 
2014;192:3719–29.
 19. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van 
der Meer JW, et al. Clinical outcome of experimental human malaria 
induced by Plasmodium falciparum-infected mosquitoes. Neth J Med. 
2005;63:52–8.
Page 8 of 8van Wolfswinkel et al. Malar J  (2017) 16:457 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 20. Woodberry T, Minigo G, Piera KA, Amante FH, Pinzon-Charry A, Good 
MF, et al. Low-level Plasmodium falciparum blood-stage infection causes 
dendritic cell apoptosis and dysfunction in healthy volunteers. J Infect 
Dis. 2012;206:333–40.
 21. Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert GJ, van de Vegte-
Bolmer M, et al. Sporozoite immunization of human volunteers under 
mefloquine prophylaxis is safe, immunogenic and protective: a double-
blind randomized controlled clinical trial. PLoS ONE. 2014;9:e112910.
 22. van Meer MP, Bastiaens GJ, Boulaksil M, de Mast Q, Gunasekera A, 
Hoffman SL, et al. Idiopathic acute myocarditis during treatment for 
controlled human malaria infection: a case report. Malar J. 2014;13:38.
 23. Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The power of malaria 
vaccine trials using controlled human malaria infection. PLoS Comput 
Biol. 2017;13:e1005255.
 24. Bertolino P, Bowen DG. Malaria and the liver: immunological hide-and-
seek or subversion of immunity from within? Front Microbiol. 2015;6:41.
 25. Obiero JM, Shekalaghe S, Hermsen CC, Mpina M, Bijker EM, Roestenberg 
M, et al. Impact of malaria preexposure on antiparasite cellular and 
humoral immune responses after controlled human malaria infection. 
Infect Immun. 2015;83:2185–96.
 26. McKenzie FE, Prudhomme WA, Magill AJ, Forney JR, Permpanich 
B, Lucas C, et al. White blood cell counts and malaria. J Infect Dis. 
2005;192:323–30.
 27. Kotepui M, Phunphuech B, Phiwklam N, Chupeerach C, Duangmano S. 
Effect of malarial infection on haematological parameters in population 
near Thailand–Myanmar border. Malar J. 2014;13:218.
 28. Olliaro P, Djimde A, Dorsey G, Karema C, Martensson A, Ndiaye JL, et al. 
Hematologic parameters in pediatric uncomplicated Plasmodium falcipa-
rum malaria in sub-Saharan Africa. Am J Trop Med Hyg. 2011;85:619–25.
 29. Hviid L, Kurtzhals JAL, Goka BQ, OliverCommey JO, Nkrumah FK, Thean-
der TG. Rapid reemergence of T cells into peripheral circulation following 
treatment of severe and uncomplicated Plasmodium falciparum malaria. 
Infect Immun. 1997;65:4090–3.
 30. Kemp K, Akanmori BD, Adabayeri V, Goka BQ, Kurtzhals JAL, Behr C, 
et al. Cytokine production and apoptosis among T cells from patients 
under treatment for Plasmodium falciparum malaria. Clin Exp Immunol. 
2002;127:151–7.
 31. Kemp K, Akanmori BD, Hviid L. West African donors have high percent-
ages of activated cytokine producing T cells that are prone to apoptosis. 
Clin Exp Immunol. 2001;126:69–75.
 32. Balde AT, Sarthou JL, Roussilhon C. Acute Plasmodium falciparum infec-
tion is associated with increased percentages of apoptotic cells. Immunol 
Lett. 1995;46(1–2):59–62.
 33. Toure Balde A, Sarthou JL, Aribot G, Michel P, Trape JF, Rogier C, et al. 
Plasmodium falciparum induces apoptosis in human mononuclear cells. 
Infect Immun. 1996;64:744–50.
 34. Kern P, Dietrich M, Hemmer C, Wellinghausen N. Increased levels of solu-
ble Fas ligand in serum in Plasmodium falciparum malaria. Infect Immun. 
2000;68:3061–3.
 35. Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, 
van Lieshout L, et al. Cytotoxic markers associate with protection against 
malaria in human volunteers immunized with Plasmodium falciparum 
sporozoites. J Infect Dis. 2014;210:1605–15.
